Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193.
Robinson
Helen M R
HM
Bratlie-Thoresen
Sigrid
S
Brown
Robert
R
Gillespie
David A F
DA
D000818:Animals; D002460:Cell Line; D000071877:Checkpoint Kinase 1; D002645:Chickens; D053903:DNA Breaks, Double-Stranded / Q000187:drug effects; D054659:Diketopiperazines; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D016195:G2 Phase / Q000187:drug effects / Q000502:physiology*; D010879:Piperazines / Q000494:pharmacology*; D011494:Protein Kinases / Q000235:genetics / Q000378:metabolism*; D059005:Topoisomerase II Inhibitors
D054659:Diketopiperazines; D010879:Piperazines; D059005:Topoisomerase II Inhibitors; C070899:4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione; D011494:Protein Kinases; D000071877:Checkpoint Kinase 1